Clinical Trials Browser

Phase 1/2 × Leukemia, Myelomonocytic, Chronic × Clofarabine × Clear all

NCT00708721 2017-06-01

Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Phase 1/2 Terminated

11 enrolled 11 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelomonocytic, Chronic